Arvinas (ARVN) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lyell Immunopharma (LYEL) has outperformed Arvinas (ARVN) over the past year, losing 27.9% versus a loss of 43.9%. Over five years, ARVN leads with a -91.8% price change compared with -92.6% for LYEL. Lyell Immunopharma is the larger company by market cap ($441.8 million vs $423.0 million), about 1.0 times the size, while Arvinas is growing revenue faster (-0.3% vs -41.0%).
Arvinas converts more of its revenue into profit, with a net margin of -30.8% versus -762355.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | LYEL |
|---|---|---|
| Share price | $6.46 | $13.80 |
| Market cap | $423.03M | $441.82M |
| 1-day change | -4.15% | +1.62% |
| YTD return | -45.53% | -55.17% |
| 1-year return | -43.92% | -27.86% |
| 5-year return | -91.75% | -92.59% |
| EPS (TTM) | $-0.08 | $-12.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $262.60M | $36.00K |
| Revenue growth (YoY) | -0.30% | -40.98% |
| Net income (latest FY) | $-80.80M | $-274.45M |
| Operating margin | -45.13% | -748344.44% |
| Net margin | -30.77% | -762355.56% |
| 52-week high | $14.51 | $45.00 |
| 52-week low | $6.33 | $7.20 |
| Distance from 52-week high | -55.48% | -69.33% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +116.72% | +172.68% |
| Average volume | 848.52K | 174.76K |
| Shares outstanding | 65.49M | 32.02M |
| Employees | 246 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LYEL has outperformed ARVN by 16.1 percentage points over the past year.
- Arvinas is more profitable, keeping -30.8 cents of every revenue dollar as net income versus -762355.6 cents for Lyell Immunopharma.
- Arvinas grew revenue faster in its latest fiscal year (-0.30% vs -40.98%).
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
ARVN vs LYEL FAQ
Which is bigger, Arvinas or Lyell Immunopharma?
Lyell Immunopharma (LYEL) is larger, with a market capitalization of $441.82M compared with $423.03M for Arvinas (ARVN).
Which stock has performed better over the past year, ARVN or LYEL?
LYEL returned -27.86% over the past 12 months, compared with -43.92% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and Lyell Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.